Advaxis, Inc. (ADXS)

Market Cap	3.92M
Revenue (ttm)	250,000
Net Income (ttm)	-15.21M
Shares Out	1.82M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 6, 2022

Volume	4,192
Open	2.00
Previous Close	2.21
Day's Range	2.00 - 2.30
52-Week Range	2.00 - 44.80
Beta	2.21
Analysts	Buy
Price Target	2.30 (+6.5%)
Earnings Date	Sep 16, 2022

About ADXS

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunothe...

• Industry: Biotechnology
• Founded: 2002
• CEO: Kenneth Berlin
• Employees: 14
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADXS

Full Company Profile

Financial Performance

In 2021, Advaxis's revenue was $3.24 million, an increase of 1,180.63% compared to the previous year's $253,000. Losses were -$17.86 million, -32.52% less than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ADXS stock is "Buy." The 12-month stock price forecast is 2.3, which is an increase of 6.48% from the latest price.

Price Target

$2.3

(6.48% upside)

Analyst Consensus: Buy

Stock Forecasts